出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/06/08 01:46:53」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
  • Sakai S1, Takeda S2, Sugimoto M3, Shimizu M4, Shimonaka Y5, Yogo K6, Hashimoto J7, Bauss F8, Endo K9.
  • Bone.Bone.2015 Dec;81:449-58. doi: 10.1016/j.bone.2015.08.004. Epub 2015 Aug 15.
  • Bisphosphonates are widely used in the treatment of osteoporosis and contribute to the reduction of bone fractures. Ibandronate (IBN) is a highly potent, nitrogen-containing bisphosphonate, which is administered orally or intravenously at extended dosing intervals. Vitamin D or active vitamin D3 der
  • PMID 26281770
  • Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
  • D'Amelio P1, Sassi F2, Buondonno I2, Fornelli G2, Spertino E2, D'Amico L3, Marchetti M2, Lucchiari M4, Roato I3, Isaia GC2.
  • Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.Osteoporos Int.2015 Dec;26(12):2785-91. doi: 10.1007/s00198-015-3189-8. Epub 2015 Jun 12.
  • We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism
  • PMID 26068297
  • Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
  • Ito M1, Tobinai M2, Yoshida S2, Hashimoto J3, Nakamura T4.
  • Journal of bone and mineral metabolism.J Bone Miner Metab.2015 Nov 27. [Epub ahead of print]
  • We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and ≥3) at screening and femoral neck (FN) bone min
  • PMID 26614597


  • Inflammatory Effects of Nitrogen-Containing Bisphosphonates (N-BPs): Modulation by Non-N-BPs
  • Biological & Pharmaceutical Bulletin 40(1), 25-33, 2017
  • NAID 130005188786
  • ビスホスホネートによる骨粗鬆症治療 (特集 骨粗鬆症update : リハビリテーションとともに) -- (骨粗鬆症に対する薬物療法)
  • 原発性骨粗鬆症に対する12カ月間のイバンドロネート注射製剤とエルデカルシトール併用治療の有効性と安全性の検討
  • 日本骨粗鬆症学会雑誌 = The journal of Japan Osteoporosis Society 2(3), 275-283, 2016
  • NAID 40021039736


Take each dose with a full glass (6 to 8 ounces) of water. Use only plain water (not mineral water) when taking an ibandronate tablet. For at least the first 60 minutes after taking an ibandronate tablet, do not lie down or recline; do not ...
Ibandronate comes as a tablet to take by mouth. The 2.5-mg tablet is usually taken once a day in the morning on an empty stomach and the 150-mg tablet is usually taken once a month in the morning on an empty ...



リンク元イバンドロン酸」「ibandronic acid



ibandronateibandronic acid

  • 骨粗鬆症治療薬;ビスホスホネート系;窒素含有

ibandronic acid」